TOOLKIT

Thank you for attending the 2022 ATOPP Summit or participating in our enduring programming! Use these resources below to further your knowledge on these topics.

• Top 10 List: How to Retain Clinical Pharmacists 
• Advocate, Recognize, Support (ARS) on a Micro & Macro Level
• ASCO Well–Being Task Force Roadmap 
•  

• Steps for Investigational New Drug (IND)
• Expanded Access 
• Project Facilitate
• Review of Project Facilitate at ASCO: Kormanik NL, et al. Project Facilitate: A Review of the FDA Oncology Center of Excellence Expanded Access Pilot Program. 2020 ASCO Annual Meeting Abstract 7023
• Assistance with Expanded Access Request: ERequest Navigator

• Hospital at Home Users Group
• CMS Acute Hospital Care at Home Waiver
• ASHP PELA Hospital at Home Conference Report
• Huntsman at Home Real World Trial: Mooney K, et al. Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol 2021;39:2586-93

• Disclosing Medical Errors the Right Way
• Case Studies in Pharmacy Ethics 
•  

Oncology Stewardship

• Case-Based Review: Ochs, MA, et al. Oncology Stewardship in Acute Myeloid Leukemia. Ann Hematol 2022; 101:1627-44
• Wolverheme Happy Hour: All Aboard the Oncology StewardSHIP (Episode 4)
• •  

Surrogate Endpoints in AML: Wolverheme Happy Hour (Episode 1)

Agents of Interest

• IDH Inhibitors in AML: Wolverheme Happy Hour – IDH Inhibitors in AML: Not So AGILE (Episode 5)
• HMA + Venetoclax (Ven)
  • Stewardship Principles of HMA + Ven
  • Institutional Approaches to Management
  • Duration of Cytopenias with Antifungals: Rausch CR, et al. Duration of Cytopenias with Concomitant Venetoclax and Azole Antifungals in Acute Myeloid Leukemia. Cancer 2021; 127:2489-99
  • Institutional Approaches to Antifungal Prophylaxis
• Oral Azacitidine (AZA)
  • Stewardship Principles of Oral AZA
  • Oral AZA Quick Facts
  • Quality of Life Outcomes: Roboz GJ, et al. Oral Azacitidine Preserves Favorable Level of Fatigue and Health-Related Quality of Life for Patients with Acute Myeloid Leukemia in Remission. Haematologica 2021; 106:3240-4
  • Cost Effectiveness: Bewersdorf JP, et al. Cost-Effectiveness Analysis of Oral Azacitidine Maintenance Therapy in Acute Myeloid Leukemia. Blood Adv 2021; 5:4686-90

• ASCO Guidelines: Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020; 38:1222-45
• Role of PARP Inhibitors in Ovarian Cancer
• BRCA Reversion Mutations: Lin KK, et al. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 2019; 9:210-9
• Graphic of BRCA Reversion Mutations
•  

• NCCN Pharmacy Directors White Paper (2021): Operationalizing the Safe and Efficient Use of Biosimilars
• Cardinal Health 2022 Biosimilars Report 
• The Age of Biosimilars in Oncology: How to Navigate Options for Your Practice and Patients (webinar)
• The Cleveland Clinic Experience: Lam SW, et al. Healthcare System Conversion to a Biosimilar: Trials and Tribulations. Am J Health Syst Pharm 2021;78:2159-63.
• Biosimilar Management at Moffitt Cancer Center: Q&A with Kenneth Komorny
• University Hospital Experience: Kar I, et al. Biosimilar Strategic Implementation at a Large Health System. Am J Health Syst Pharm 2022;79:268-75.
• Act4Biosimilars

If you would like to see more resources about Biosimilars, click here for our 2021 Biosimilars in Oncology Webinar toolkit.